EGF

EGF Full Name

epidermal growth factor

EGF Introduction

Epidermal growth factor (EGF) is a small but highly potent signaling protein that plays a fundamental role in regulating cell growth, proliferation, and survival in many tissues of the human body. Discovered as one of the first growth factors capable of stimulating epidermal cell proliferation, EGF functions primarily through binding to the epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine kinase that activates multiple downstream signaling pathways such as MAPK, PI3K/AKT, and JAK/STAT. These pathways coordinate essential biological processes including cell cycle progression, tissue repair, and differentiation. Because of its central role in cellular signaling, EGF has become a key molecular target in biomedical research, especially in studies focusing on cell communication, tumor biology, and targeted therapeutic development. For researchers investigating cell proliferation mechanisms or developing anti-cancer strategies, understanding the biological functions of EGF is essential for interpreting disease progression and identifying potential intervention points.

Beyond its physiological role in tissue regeneration and wound healing, dysregulation of EGF signaling has been strongly associated with cancer initiation and progression. In particular, studies of colon cancer stem cells have demonstrated that the EGF signaling pathway plays a critical regulatory role in controlling both proliferation and apoptosis. Abnormal activation of this pathway can enhance tumor cell survival, promote uncontrolled growth, and contribute to the development of resistance to chemotherapy. These findings highlight the importance of EGF-mediated signaling in maintaining cancer stem cell populations, which are often responsible for tumor recurrence and treatment failure. As a result, targeting the EGF–EGFR signaling axis has become a major focus in oncology research, with scientists exploring how modulation of this pathway may improve chemosensitivity and suppress tumor progression.

Emerging evidence also suggests that genetic variations in the EGF gene and abnormal expression levels may influence susceptibility to multiple cancers. For example, polymorphisms such as the EGF A61G variant have been linked to altered serum EGF levels and increased risk of gastric cancer, suggesting that EGF may serve as a potential biomarker for cancer susceptibility and prognosis. In addition, bioinformatics analyses of papillary renal cell carcinoma have identified EGF as a key gene associated with tumor development, further supporting its role in oncogenic signaling networks. These discoveries not only expand the understanding of EGF in cancer biology but also highlight the growing need for reliable detection and analytical tools to study EGF expression, genetic variation, and signaling activity in clinical and research settings. Accurate monitoring of EGF-related biomarkers may therefore contribute to earlier diagnosis, better patient stratification, and the development of more precise targeted therapies.

Alternate Names for EGF

EGF; epidermal growth factor; URG; HOMG4; pro-epidermal growth factor; beta-urogastrone;

• 1.Feng Y, et al.; EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. Cell Prolif. 2012, 45(5):413-9.
  2.Cacina C, et al.; Analyses of EGF A61G Gene Variation and Serum EGF Level on Gastric Cancer Susceptibility and Clinicopathological Parameters. Anticancer Res. 2015, 35(5):2709-13. PMID: 25964549.